The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Arcturus And The Struggle For Substantive Justice. Legal News and Analysis - India - Intellectual Property - Conventus Law ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported its first-quarter 2025 financial results, revealing a significant revenue shortfall and a net loss that missed analyst expectations. Despite these ...

Based on the current pipeline and programs, the cash runway is expected to extend into 2028 with the re-allocation of resources to the therapeutics programs. The Arcturus logo and other trademarks ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported its first-quarter 2025 financial results, revealing a significant revenue shortfall and a net loss that missed analyst expectations. Despite the ...

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.